Preclinical evidence for the potential of a bivalent fHBP vaccine to preventNeisseria meningitidisSerogroup C Disease
Open Access
- 1 January 2011
- journal article
- Published by Taylor & Francis in Human Vaccines
- Vol. 7 (sup1) , 68-74
Abstract
A bivalent factor H binding protein (fHBP) vaccine for the prevention of disease caused by Neisseria meningitidis serogroup B is currently in clinical development. Since fHBP is also expressed by other meningococcal serogroups, anti-fHBP antibodies may have bactericidal activity against meningococci independent of serogroup. To begin examining the susceptibility of other meningococcal serogroups to anti-fHBP antibodies, meningococcal serogroup C invasive isolates (n = 116) were collected from the Centers for Disease Control and Prevention’s Active Bacterial Core surveillance (ABCs) sites during 2000–2001. These isolates were analyzed for the presence of the fhbp gene. All serogroup C isolates contained the gene, and sequence analysis grouped the proteins into two subfamilies, A and B. Flow cytometry analysis demonstrated that fHBP was expressed on the surface of ~70% of isolates in vitro with varying levels of expression. fHBP was accessible to antibodies on the cell surface even in the presence of the polysaccharide capsule. Nine isolates from different geographic regions were identified which harboured an identical single nucleotide deletion that could result in a truncated subfamily B fHBP. Analysis by flow cytometry using a polyclonal fHBP antibody preparation revealed that a subpopulation of each of these isolates expressed fHBP. Rabbit and non-human primate immune sera generated with bivalent fHBP vaccine were tested for bactericidal activity against a panel of diverse serogroup C clinical isolates using human complement. Sera from both species demonstrated serum bactericidal antibody activity against the serogroup C isolates tested. These promising findings suggest that a bivalent fHBP vaccine may be capable of providing protection against meningococcal disease caused by both serogroup C and B.Keywords
This publication has 12 references indexed in Scilit:
- Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United StatesVaccine, 2011
- Changes inNeisseria meningitidisDisease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal DiseaseClinical Infectious Diseases, 2010
- Variation of the factor H-binding protein of Neisseria meningitidisMicrobiology, 2009
- Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup BNeisseria meningitidisThe Journal of Infectious Diseases, 2009
- Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharideVaccine, 2009
- Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086Journal of Biological Chemistry, 2009
- High-throughput imaging of bacterial colonies grown on filter plates with application to serum bactericidal assaysJournal of Immunological Methods, 2004
- Vaccine Potential of theNeisseria meningitidis2086 LipoproteinInfection and Immunity, 2004
- Vaccination against Neisseria meningitidis Using Three Variants of the Lipoprotein GNA1870Journal of Experimental Medicine, 2003
- Antibodies to Polysialic Acid and its N-Propyl Derivative: Binding Properties and Interaction with Human Embryonal Brain GlycopeptidesThe Journal of Infectious Diseases, 1995